Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562754568> ?p ?o ?g. }
- W2562754568 abstract "PD-L1 expressed in the tumor microenvironment regulates Th1 immune responses and mediates cancer immune evasion through interactions with PD-1 or B7.1 receptors on activated T cells. MPDL3280A, an engineered human monoclonal antibody, targets PD-L1 and inhibits its function. To identify immunologic predictive and pharmacodynamic biomarkers of MPDL3280A treatment, we performed a comprehensive analysis of tumors and blood samples collected at baseline and/or on treatment from ≈280 patients with locally advanced or metastatic solid tumors, including NSCLC, RCC, melanoma and bladder cancer. Regardless of tumor type, clinical responses were characterized by PD-L1 expression, the presence of markers of T cell activation (Th1 gene signature and CTLA4), and the absence of fractalkine at baseline in the tumor microenvironment. Elevated baseline expression of IFN-γ and IFN-γ-inducible genes (e.g., IDO1 and CXCL9) was associated with MPDL3280A response in melanoma but not NSCLC or RCC. On treatment, responding tumors showed increased infiltration of Th1-dominant immune infiltrate and evidence of adaptive PD-L1 up-regulation. In contrast, progressing tumors displayed the following patterns of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression: (1) few/no TILs and absent PD-L1 expression (immunologic ignorance), (2) TILs present with minimal/no PD-L1 expression (non-functional immune responses), or (3) TILs residing solely around the tumor cell mass outer edge (excluded infiltrate), suggesting that resistance to MPDL3280A may be associated with impaired T cell trafficking and/or function.Profiling of ≈180 circulating biomarkers revealed that plasma concentrations of IL-18 and interferon-inducible T cell alpha chemoattractant (ITAC) increased in all patients following MPDL3280A treatment, representing a pharmacodynamic measurement of PD-L1 inhibition. In addition, analysis of PBMC showed an increase in T cell activation, as measured by IFN-γ and granzymes A and B gene expression in responders following MPDL3280A treatment, consistent with the observations in responding tumors. Baseline soluble PD-L1 was not associated with response. Some indication-specific biomarkers, such as plasma VEGF, decreased in responders with RCC but not with other indications. In NSCLC, a decrease in tumor burden markers, CA-125 and CEA, was associated with response. Similarly, IL-6 and IL-8 were differentially expressed on treatment in responders vs non-responders. Additionally, responders exhibited a decrease in circulating tumor DNA (ctDNA) in plasma, suggesting that ctDNA may be used to monitor MPDL3280A clinical activity in NSCLC.In conclusion, these data provide general and indication-specific mechanistic insights into immune checkpoint inhibition, potential mechanisms of response and resistance, as well as identification of potential predictive and pharmacodynamic biomarkers of anti-PD-L1/PD-1 clinical activity across multiple tumor types." @default.
- W2562754568 created "2017-01-06" @default.
- W2562754568 creator A5001204975 @default.
- W2562754568 creator A5008593691 @default.
- W2562754568 creator A5009218139 @default.
- W2562754568 creator A5015761216 @default.
- W2562754568 creator A5015912578 @default.
- W2562754568 creator A5021624793 @default.
- W2562754568 creator A5024113581 @default.
- W2562754568 creator A5029105145 @default.
- W2562754568 creator A5030413229 @default.
- W2562754568 creator A5031740209 @default.
- W2562754568 creator A5037677978 @default.
- W2562754568 creator A5038215538 @default.
- W2562754568 creator A5038972626 @default.
- W2562754568 creator A5040064532 @default.
- W2562754568 creator A5052061341 @default.
- W2562754568 creator A5054852321 @default.
- W2562754568 creator A5066541232 @default.
- W2562754568 creator A5068171378 @default.
- W2562754568 creator A5070967174 @default.
- W2562754568 creator A5079272191 @default.
- W2562754568 creator A5086309026 @default.
- W2562754568 creator A5087092015 @default.
- W2562754568 creator A5088101292 @default.
- W2562754568 creator A5090977453 @default.
- W2562754568 date "2014-12-05" @default.
- W2562754568 modified "2023-09-30" @default.
- W2562754568 title "Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A" @default.
- W2562754568 doi "https://doi.org/10.7490/f1000research.1097332.1" @default.
- W2562754568 hasPublicationYear "2014" @default.
- W2562754568 type Work @default.
- W2562754568 sameAs 2562754568 @default.
- W2562754568 citedByCount "0" @default.
- W2562754568 crossrefType "journal-article" @default.
- W2562754568 hasAuthorship W2562754568A5001204975 @default.
- W2562754568 hasAuthorship W2562754568A5008593691 @default.
- W2562754568 hasAuthorship W2562754568A5009218139 @default.
- W2562754568 hasAuthorship W2562754568A5015761216 @default.
- W2562754568 hasAuthorship W2562754568A5015912578 @default.
- W2562754568 hasAuthorship W2562754568A5021624793 @default.
- W2562754568 hasAuthorship W2562754568A5024113581 @default.
- W2562754568 hasAuthorship W2562754568A5029105145 @default.
- W2562754568 hasAuthorship W2562754568A5030413229 @default.
- W2562754568 hasAuthorship W2562754568A5031740209 @default.
- W2562754568 hasAuthorship W2562754568A5037677978 @default.
- W2562754568 hasAuthorship W2562754568A5038215538 @default.
- W2562754568 hasAuthorship W2562754568A5038972626 @default.
- W2562754568 hasAuthorship W2562754568A5040064532 @default.
- W2562754568 hasAuthorship W2562754568A5052061341 @default.
- W2562754568 hasAuthorship W2562754568A5054852321 @default.
- W2562754568 hasAuthorship W2562754568A5066541232 @default.
- W2562754568 hasAuthorship W2562754568A5068171378 @default.
- W2562754568 hasAuthorship W2562754568A5070967174 @default.
- W2562754568 hasAuthorship W2562754568A5079272191 @default.
- W2562754568 hasAuthorship W2562754568A5086309026 @default.
- W2562754568 hasAuthorship W2562754568A5087092015 @default.
- W2562754568 hasAuthorship W2562754568A5088101292 @default.
- W2562754568 hasAuthorship W2562754568A5090977453 @default.
- W2562754568 hasConcept C121608353 @default.
- W2562754568 hasConcept C126322002 @default.
- W2562754568 hasConcept C159654299 @default.
- W2562754568 hasConcept C203014093 @default.
- W2562754568 hasConcept C2776107976 @default.
- W2562754568 hasConcept C2777658100 @default.
- W2562754568 hasConcept C2777701055 @default.
- W2562754568 hasConcept C2778326572 @default.
- W2562754568 hasConcept C2780674031 @default.
- W2562754568 hasConcept C2780851360 @default.
- W2562754568 hasConcept C2781053074 @default.
- W2562754568 hasConcept C502942594 @default.
- W2562754568 hasConcept C71924100 @default.
- W2562754568 hasConcept C8891405 @default.
- W2562754568 hasConceptScore W2562754568C121608353 @default.
- W2562754568 hasConceptScore W2562754568C126322002 @default.
- W2562754568 hasConceptScore W2562754568C159654299 @default.
- W2562754568 hasConceptScore W2562754568C203014093 @default.
- W2562754568 hasConceptScore W2562754568C2776107976 @default.
- W2562754568 hasConceptScore W2562754568C2777658100 @default.
- W2562754568 hasConceptScore W2562754568C2777701055 @default.
- W2562754568 hasConceptScore W2562754568C2778326572 @default.
- W2562754568 hasConceptScore W2562754568C2780674031 @default.
- W2562754568 hasConceptScore W2562754568C2780851360 @default.
- W2562754568 hasConceptScore W2562754568C2781053074 @default.
- W2562754568 hasConceptScore W2562754568C502942594 @default.
- W2562754568 hasConceptScore W2562754568C71924100 @default.
- W2562754568 hasConceptScore W2562754568C8891405 @default.
- W2562754568 hasLocation W25627545681 @default.
- W2562754568 hasOpenAccess W2562754568 @default.
- W2562754568 hasPrimaryLocation W25627545681 @default.
- W2562754568 hasRelatedWork W2203074247 @default.
- W2562754568 hasRelatedWork W2318979033 @default.
- W2562754568 hasRelatedWork W2323356988 @default.
- W2562754568 hasRelatedWork W2340296324 @default.
- W2562754568 hasRelatedWork W2400310528 @default.
- W2562754568 hasRelatedWork W2591239368 @default.
- W2562754568 hasRelatedWork W2734739695 @default.
- W2562754568 hasRelatedWork W2886691465 @default.
- W2562754568 hasRelatedWork W2890052178 @default.
- W2562754568 hasRelatedWork W2929034286 @default.